Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Igor Mrdovic

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
The Canadian Journal of Cardiology|March 7, 2013
Sex-related analysis of short- and long-term clinical outcomes and bleeding among patients treated with primary percutaneous coronary intervention: an evaluation of the RISK-PCI dataIgor Mrdovic, Lidija Savic, Milika Asanin, et al.
Heart and Vessels|September 15, 2012
Usefulness of the RISK-PCI score to predict stent thrombosis in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a substudy of the RISK-PCI trialIgor Mrdovic, Lidija Savic, Ratko Lasica, et al.
Drug Metabolism and Personalized Therapy|April 7, 2018
Homocysteine is the confounding factor of metabolic syndrome-confirmed by siMS scoreBranko Srećković, Ivan Soldatovic, Emina Colak, et al.
Clinical Laboratory|May 10, 2016
B-type Natriuretic Peptide and RISK-PCI Score in the Risk Assessment in Patients with STEMI Treated by Primary Percutaneous Coronary InterventionMilika Asanin, Igor Mrdovic, Lidija Savic, et al.
International Journal of Cardiology|June 14, 2011
Predicting 30-day major adverse cardiovascular events after primary percutaneous coronary intervention. The RISK-PCI scoreIgor Mrdovic, Lidija Savic, Gordana Krljanac, et al.
Diabetes & Metabolic Syndrome|September 8, 2016
Homocysteine is a marker for metabolic syndrome and atherosclerosisBranko Sreckovic, Vesna Dimitrijevic Sreckovic, Ivan Soldatovic, et al.
International Journal of Cardiology|May 26, 2012
Impact of high post-loading platelet aggregation on 30-day clinical outcomes after primary percutaneous coronary intervention. The antiplatelet regimen tailoring after primary PCI (ART-PCI) trialIgor Mrdovic, Lidija Savic, Gordana Krljanac, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|April 23, 2013
Simple risk algorithm to predict serious bleeding in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: RISK-PCI bleeding scoreIgor Mrdovic, Lidija Savic, Gordana Krljanac, et al.
Blood Pressure|February 6, 2015
Prognostic significance of dipping in older hypertensive patientsMatej Bendzala, Peter Kruzliak, Ludovit Gaspar, et al.
International Journal of Cardiology|July 12, 2005
Significance of recurrences of new atrial fibrillation in acute myocardial infarctionMilika Asanin, Jovan Perunicic, Igor Mrdovic, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
The Canadian Journal of Cardiology|March 7, 2013
Sex-related analysis of short- and long-term clinical outcomes and bleeding among patients treated with primary percutaneous coronary intervention: an evaluation of the RISK-PCI dataIgor Mrdovic, Lidija Savic, Milika Asanin, et al.
Heart and Vessels|September 15, 2012
Usefulness of the RISK-PCI score to predict stent thrombosis in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a substudy of the RISK-PCI trialIgor Mrdovic, Lidija Savic, Ratko Lasica, et al.
Drug Metabolism and Personalized Therapy|April 7, 2018
Homocysteine is the confounding factor of metabolic syndrome-confirmed by siMS scoreBranko Srećković, Ivan Soldatovic, Emina Colak, et al.
Clinical Laboratory|May 10, 2016
B-type Natriuretic Peptide and RISK-PCI Score in the Risk Assessment in Patients with STEMI Treated by Primary Percutaneous Coronary InterventionMilika Asanin, Igor Mrdovic, Lidija Savic, et al.
International Journal of Cardiology|June 14, 2011
Predicting 30-day major adverse cardiovascular events after primary percutaneous coronary intervention. The RISK-PCI scoreIgor Mrdovic, Lidija Savic, Gordana Krljanac, et al.
Diabetes & Metabolic Syndrome|September 8, 2016
Homocysteine is a marker for metabolic syndrome and atherosclerosisBranko Sreckovic, Vesna Dimitrijevic Sreckovic, Ivan Soldatovic, et al.
International Journal of Cardiology|May 26, 2012
Impact of high post-loading platelet aggregation on 30-day clinical outcomes after primary percutaneous coronary intervention. The antiplatelet regimen tailoring after primary PCI (ART-PCI) trialIgor Mrdovic, Lidija Savic, Gordana Krljanac, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|April 23, 2013
Simple risk algorithm to predict serious bleeding in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: RISK-PCI bleeding scoreIgor Mrdovic, Lidija Savic, Gordana Krljanac, et al.
Blood Pressure|February 6, 2015
Prognostic significance of dipping in older hypertensive patientsMatej Bendzala, Peter Kruzliak, Ludovit Gaspar, et al.
International Journal of Cardiology|July 12, 2005
Significance of recurrences of new atrial fibrillation in acute myocardial infarctionMilika Asanin, Jovan Perunicic, Igor Mrdovic, et al.
Pageof 5